Concepedia
Institution (Healthcare)
Regional Clinical Hospital named after II Mechnikov
Also Known As
Dnipropetrovsk Oblast Clinical Hospital named after II Mechnikov, Regional Clinical Hospital named after II Mechnikov
526
Publications
15.7K
Citations
29
Authors
114
Concepts
Home
1
20
36
3.3K
2
8
9
223
3
10
4
15
5
×
All Concepts
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga, Ian Bradbury, Holger Eidtmann, +23
The Lancet
Breast OncologyOncologyPathologyBreast CancerCancer Treatment +3
2012
1.3K
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo, +26
New England Journal of Medicine
2017
949
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, +10
Journal of Clinical Oncology
2010
630
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Martin Reck, Igor Bondarenko, Alexander Luft, +7
Annals of Oncology
First-line TherapyOncologyMulticenter Phase 2PharmacologyClinical Trials +7
606
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Thomas E. Hutson, Vladimir Lesovoy, V.P. Stus, +6
The Lancet Oncology
First-line TherapyUrologyAxitinib Versus SorafenibMetastatic Renal-cell CarcinomaGenitourinary Cancer +6
2013
404
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.
David Cunningham, Niall C. Tebbutt, André M. Murad, +15
First-line TherapyEsophageal CancerImmunologyGastroenterologyPathology +15
2015
143
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J. Matasar, Marcelo Capra, Muhıt Özcan, +26
Lymphoid NeoplasiaMedicinePharmacologyClinical TrialsTreatment Option +5
2021
132
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, +288
Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety +5
2019
111
Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
Paolo Ghia, Andrzej Pluta, Małgorzata Wach, +15
HemaSphere
2022
95
Ceftobiprole for Treatment of Complicated <i>Staphylococcus aureus</i> Bacteremia
Thomas L Holland, Sara E. Cosgrove, Sarah B. Doernberg, +20
2023
87
Page 1